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ICU length of stayAbstract Background: Statins anti-inﬂammatory and antioxidant properties improve vascular
function in septic patients. The aim of this prospective study was to assess vasopressor effect and
safety of rosuvastatin therapy in septic patient.
Methods: One hundred and eight patients admitted to intensive care unit (ICU) with suspected or
conﬁrmed infection plus at least 2 systemic inﬂammatory response syndrome criteria were included
in this prospective double-blinded randomized two groups’ parallel study. Group R received stan-
dard therapy and rosuvastatin 20 mg/day and Group C received standard therapy with placebo/day
for 14 days.
The primary endpoint was number of acceptable blood pressure and systemic perfusion days
(ABPSPD). Secondary outcome included time to initial ABPSPD, vasopressor dose and duration,
arterial lactate, organ dysfunction or failure free days, ICU and hospital stay, 28 ICU and hospital
mortality, CPK and transaminases level.
Results: The number of ABPSPD was signiﬁcantly increased 11(3) vs. 8 (3) (p= 0.0001), with a
shorter time to initial ABPSPD 18(21) vs. 41(37) h (p= 0.0001) in Group R than Group C. Nor-
epinephrine dose 0.8 (0.5) vs. 1.6 (0.6) and duration 3(2) vs. 6(3) were signiﬁcantly reduced in Group
R with no signiﬁcant elevation in transaminases or CPK.
Conclusions: Rosuvastatin 20 mg/day in septic patients increased number ABPSPD, decreased
time to initial ABPSPD, norepinephrine dose and duration, with no signiﬁcant elevation in trans-
aminases or CPK.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Microvascular circulation and endothelial cell dysfunction is the
core pathogenesis of sepsis [1]. Induction of inﬂammatory cyto-
kines decreases the vascular tone, and causes severe hypoten-
sion, inadequate organ perfusion, multiple organ dysfunction
and failure [2,3]. Vasopressors are used to increase blood pres-
sure and improve tissue perfusion. However, in sepsis the
decreased reactivity to exogenously administered catecholamine
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strated that the vascular effect of statins was independent of li-
pid lowering effect and the anti-inﬂammatory and antioxidant
properties [5,6] caused the improvement in vascular function.
The aim of this prospective study was to assess vasopressor
effect and safety of rosuvastatin therapy in septic patient.
2. Methods
The protocol was approved by our institution medical board
and patients’ guardian or next of kin gave informed written
consent. One hundred and eight patients who met the inclusion
criteria: age >18 years old, of both sexes, with the presence of
clinically suspected or conﬁrmed infection plus at least two of
the systemic inﬂammatory response syndrome criteria (temper-
ature > 38 C or <36 C, heart rate >90 beats/min, respira-
tory rate >20 breaths/min or arterial Pco2 < 32 mmHg,
WBC count > 12,000/mm3 or <4000/mm3 or >10% imma-
ture forms) with organ dysfunction, hypoperfusion or hypo-
tension, and initiated appropriate antimicrobial therapy
admitted to Intensive Care Unit Ain Shams University Hospi-
tal during the period of May 2011 to May 2012 were assigned
randomly using computerized program in this randomized
prospective double blinded study to one of the two parallel
groups (Control group n= 54 patients and 54 patients in
Rosuvastatin group). Patients were randomly assigned after
admission to the ICU by opening sequentially numbered opa-
que envelopes. Exclusion criteria were as follows: pregnancy,
A severe moribund state, an anticipated ICU stay of less than
24 h, serum creatine kinase (CPK) > 5 times the upper limit of
normal range, liver transaminases (AST and ALT) > 3 times
the upper limit of normal range, contraindication to enteral
nutrition, chronic renal failure, treatment of statins within
the previous 30 days, high risk of rhabdomyolysis (multiple
trauma, extensive burn and crush injuries), serum creatine
> 2 mg/dl allergy to statins and concurrent treatment with
anticoagulants as warfarin, cimetidine, ketoconazole, cyclo-
sporine, cloﬁbrate, fenoﬁbrate, gemﬁbrozil, niacin, or speciﬁc
HIV protease inhibitors.
All patients received standard protocol of Intensive Care
Unit management in Ain Shams University Hospital using
early goal directed therapy of sepsis. Patients were given intra-
venous ﬂuids resuscitation, antimicrobials, stress ulcer prophy-
laxis (proton pump inhibitor), enteral nutrition, analgesic,
antipyretics, and prophylactic low molecular weight heparin.
Severe sepsis and septic shock were deﬁned according to the
American College of Chest Physicians/Society for Critical Care
Medicine Consensus Conference on sepsis and organ failure [7].
Severe sepsis was deﬁned as sepsis associated with organ dys-
function, hypoperfusion or hypotension (hypoperfusion abnor-
malities as lactic acidosis, oliguria or an acute alteration in
mental status), whereas septic shock was deﬁned as sepsis-in-
duced hypotension MABP < 65 mmHg despite adequate ﬂuid
resuscitation associated with hypoperfusion abnormalities or
organ dysfunction (oliguria < 0.5 ml/kg/h for >2 h, lactic aci-
dosis, and alteration in mental status).
Norepinephrine was started at 0.5–1 mcg/kg/min and ti-
trated to maximum dose: 5 mcg/kg/min till mean arterial
blood pressure P65 mmHg. The norepinephrine infusion rate
was adjusted by the nursing staff blinded to the study groups(at least every hour) to the minimal dose necessary to maintain
mean arterial blood pressure P65 mmHg [8].
The study group (Group R) received the standard protocol
therapy and rosuvastatin 20 mg/day starting from the onset of
the diagnosis of sepsis for 14 days whereas, the control group
(Group C) received only the standard protocol therapy with
identically appearing placebo preparation tablet that resembles
the statin/day starting from the onset of the diagnosis of sepsis
for 14 days as well.
For all patients general characteristics were recorded; Age,
gender, body mass index, severity of illness on APACHE II
score, and SOFA scores (recorded once daily), cause of admis-
sion (medical or surgical), origin of sepsis and causative organ-
ism, need for mechanical ventilation on admission. Arterial
lactate concentrations and blood gases were recorded twice
daily. Results of routine laboratory tests, blood cultures, and
cultures of specimen sampled from site of infection were also
recorded.
During the study period careful neurological and cardiac
examinations were conducted daily for all patients. Routine
ECG, continuous invasive bloodpressure, SPO2, aswell as hourly
CVP, and UOP were also monitored. Central venous blood gas
sampling was done to monitor oxygenation as indicated to
achieve the early goal directed therapy. Patients were mechani-
cally ventilated if they met the criteria of mechanical ventilation
and weaned upon improvement according to protocols.
Norepinephrine dose and duration were recorded. Any sus-
pected side effects of statins were assessed and recorded by
measuring daily serum aminotransferase (ALT and AST)
and CPK levels. Statin therapy was stopped if the patient suf-
fered intolerance as vomiting, aminotransferase elevation more
than three times the upper normal level, or increase in serum
CPK above ﬁve times the upper normal level and restarted
after resolution.
The primary endpoint was the number of days with accept-
able blood pressure and systemic perfusion (ABPSPD) up to
14 day. The ABPSPD deﬁned as a mean arterial pressure
(MAP)P 65 mmHg, urine output > 2 ml/kg/h, and central
venous oxygen saturation (ScvO2)P 70%, with no increase
in the infusion of vasopressors or inotropic therapy maintained
for four hours.
Secondary outcome included time taken to achieve initial
ABPSPD, the dose and duration of vasopressor infused for
14 days, arterial lactate ,the number of organ dysfunction-free,
and organ failure free days as assessed by SOFA score up to
day 14, ICU length of stay, length of hospital stay, and
twenty-eight ICU mortality or hospital mortality.
Evaluation of safety of rosuvastatin was assessed as eleva-
tion of serum CPK above ﬁve times the upper normal level
and transaminases level above three times the upper normal le-
vel for the study period.
Organ dysfunction and organ failure were deﬁned by a
Sequential Organ Failure Assessment (SOFA) score above
one and above two, respectively [8]. Organ failure or dysfunc-
tion -free days were deﬁned as the number of days between
ICU admission (day 1) and day 14 with the patient alive with-
out any organ failure. In case of ICU death before day 14, or-
gan failure-free days were considered equal to zero. Patients
discharged from ICU before day 14 were considered free from
organ failure after ICU discharge.
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Statistical analysis was performed using SPSS version 15.0
package (SPSS Inc, Chicago, IL, USA). Data were expressed
as Mean (SD) for quantitative parametric measures and com-
parison done using independent t-test. Categorical data were
expressed as both number and percentage and compared using
the Chi-square test or exact Fisher test. Quantitative variables
are reported as median and compared using the nonparametric
Mann–Whitney test. Logistic regression analysis was done to
adjust for other covariates that may affect the outcome such
as age, APACHE II score, sex, body mass index, type of pa-
tients, SOFA score, sepsis characteristics ,need for mechanical
ventilation on admission. A P value less than 0.05 was consid-
ered signiﬁcant, whereas P value less than 0.0001 was consid-
ered signiﬁcant highly signiﬁcant. A sample size of 98
patients (49 patients per group) was estimated at a power of
study = 80% and a= 0.05, using Power and Sample size cal-
culation 2.1.31 program (PS). A pilot study of 10 patients was
carried out. A mean difference of 2 with SD 3.5 for the number
of days with acceptable blood pressure and systemic perfusionTable 1 Patients characteristics, sepsis characteristics and demogra
mean rank APACHE II score, and SOFA score, number and percenta
and need for mechanical ventilation on admission.
Patients characteristics and demographic data Grou
Age (year) mean (SD) 35 (8
APACHE II score (median and mean rank) 25 (5
Sex
Male 33 (6
Female 21 (3
Body mass index (kg/m2) mean (SD) 28 (5
Type of patients (n) %
Medical 32 (5
Surgical 22 (4
SOFA score at screening (median and mean rank) 9 (57
Sepsis characteristic
Severe sepsis (n) % 33(61
Septic shock (n) % 21(39
Need for mechanical ventilation on admission n (%) 13(24
Type of infection
Hospital acquired infection 38(70
Community acquired infection 16(30
Origin of sepsis, n (%)
Lungs 15 (2
Abdomen 13 (2
Urogenital 7 (13
Skin, bone and soft tissue 5 (9%
Other 3 (6%
Unknown 1 (2%
Neurological system 4 (7%
Ear nose and throat 2 (4%
Causative organism, n (%)
Gram-negative bacteria 22 (4
Gram-positive bacteria 18 (3
Other class 14 (2
\P< 0.05 indicates signiﬁcant difference between groups. APACHE II sc
sequential organ failure assessment.(ABPSPD) was considered for calculation of sample size. 10%
was added to the sample to cover for dropouts.
4. Results
One hundred and thirty-ﬁve patients admitted to Intensive
Care Unit Ain Shams University Hospital during the study
period was assessed for randomization, 4 patients were less
than 18 years, 5 patients were multiple trauma patients and 2
patients suffered crushed injuries, 5 patients suffered elevations
in liver enzymes more than 3 times due to a hepatic disease, 3
patients had a chronic kidney disease on hemodialysis, and 3
patients were admitted with acute abdomen which contraindi-
cated enteral feeding, 3 patients were already on current treat-
ment with statins, the serum creatine was more than 2 mg/dl in
2 patients. In the study group consisting of 108 patients there
was a male predominance 59%, mean age 36 (9), body mass
index 27 (4), median APACHEII score 25, SOFA score 9.
Fifty-two percent of patients were deﬁned as severe sepsis
and 47% deﬁned as septic shock. The study group included
54 patients in the rosuvastatin group (Group R) and 54 inphic data. Mean (SD) for age and body mass index, median and
ge for sex, Origin of sepsis , type of infection, causative organism,
p R (n 54) Group C (n 54) Signiﬁcance
) 37 (9) 0.4
9) 24 (50) 0.2
0.7
1%) 31 (57%)
9%) 23 (43%)
) 26(4) 0.2
0.2
9%) 25 (46%)
1%) 29 (54%)
) 8 (52) 0.3
%) 37(69%) 0.4
%) 17(31%) 0.4
%) 18(33%) 0.2
0.7
%) 36 (67%)
%) 18 (33%)
0.8
8%) 12 (22%)
4%) 10 (19%)
%) 6 (11%)
) 7 (13%)
) 5 (9%)
) 6 (11%)
) 4 (7%)
) 5 (9%)
0.5
1%) 25 (46%)
3%) 17 (31%)
6%) 12 (22%)
ore, is the acute physiologic and chronic health score, SOFA score is
Figure 1 Boxplot showing acceptable blood pressure and systemic perfusion (ABPSPD) days, \highly signiﬁcance is p< 0.001, data is
presented as mean (SD).
Figure 3 Showing organ failure free days[mean(SD)]. Organ
failure was deﬁned by a sequential organ failure assessment
(SOFA)\ above two for the appropriate function. \P< 0.05
indicates signiﬁcant difference between groups.
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ence within the groups regarding the patient characteristics,
sepsis characteristics and demographic data (Table 1). Logistic
regression analysis was done to adjust for other covariates that
may affect the outcome between groups, age (p= 0.5),
APACHE II score (p= 0.3), sex (p= 0.6), body mass index
(p= 0.1), type of patients (p= 0.1), SOFA score (p= 0.3),
sepsis characteristics (p= 0.5), origin of sepsis (p= 0.3), caus-
ative organism (p= 0.2), and need for mechanical ventilation
on admission (p= 0.2).
The number of days with acceptable blood pressure and
systemic perfusion (ABPSPD) was signiﬁcantly higher
(p= 0.0001) in Group R 11(3) than Group C 8 (3) (Fig. 1),
with a signiﬁcantly shorter time to reach acceptable blood
pressure and systemic perfusion in Group R than Group C
(p= 0.0001) (Table 2), and signiﬁcantly increase in the num-
ber of organ dysfunction-free days 8(3) vs. 4 (3)
(p= 0.0001), and organ failure free days 10(3) vs. 6(3)
(p= 0.0001) in Group R than Group C (Figs. 2 and 3).
Norepinephrine dose (ug/kg/min) (p= 0.0001) and duration
(p= 0.0001), arterial lactate level (p= 0.0001), number of pa-
tients requiring mechanical ventilation (p= 0.02) and the
duration of mechanical ventilation (p= 0.0001) were signiﬁ-
cantly less in Group R than Group C. There was a decrease
in length of ICU stay, ICU mortality, in hospital stay, andFigure 2 Boxplot showing organ dysfunction free day-
s[mean(SD)]. Organ dysfunction was deﬁned by a sequential
organ failure assessment (SOFA) score above one for the
appropriate function. \p< 0.05 indicates signiﬁcant difference
between groups.hospital mortality within both groups, but did not reach statis-
tical signiﬁcance (Table 2, Fig. 4).
Treatment with rosuvastatin 20 mg for 14 days was safe as
the number of patients with signiﬁcant elevation in either ser-
um CPK and/or transaminases level (ALT and AST) was not
signiﬁcantly different in Group R than Group C during the
study period (Table 3).
5. Discussion
In this study we investigated the effect of Rosuvastatin 20 mg/
day starting from the onset of the diagnosis of sepsis for
14 days. There was an increased number of days with accept-
able blood pressure and systemic perfusion (ABPSPD) accom-
panied by a shorter time to reach ABPSPD , smaller doses and
shorter duration of norepinephrine used in Group R than
Group C.
In sepsis the cardiovascular disturbance and multisystem
organ failure is caused by endotoxins and cytokines [2,3]. This
hypotensive response occurs in the later stage of sepsis due to
failure of endothelial mechanism controlling vascular smooth
muscle contractility [9–11].
Vascular endothelial dysfunction in sepsis is associated with
loss of endothelial nitric oxide synthase (e NOS) which is
important for maintaining normal endothelial cell surface
Table 2 Outcome parameters; mean (SD) for time to initial stabilization norepinephrine doses, norepinephrine duration, arterial
lactate, duration of invasive mechanical ventilation, ICU length of stay and hospital length of stay. While frequency and percentages
for invasive mechanical ventilation, ICU mortality and Hospital mortality.
Outcome parameters Group R (n 54) Group C (n 54) Signiﬁcance
Time to reach ABPSP (hours) 18(21) 41(37) P= 0.0001**
Norepinephrine doses (dose in ug/kg/min) 0.8(0.5) 1.6 (0.6) P= 0.0001**
Norepinephrine duration (days) 3(2) 6 (3) P= 0.0001**
Arterial lactate (mg/dl) 4(2) 5(2) P= 0.0001**
Invasive mechanical ventilation, n (%) 16(30%) 27(50%) 0.02*
Duration of invasive mechanical ventilation (days) 6(4) 9(5) 0.001**
ICU mortality, n (%) 12(22%) 16(30%) 0.3
ICU length of stay(days) 11(5) 13(5) 0.1
Hospital mortality n (%) 17 (31%) 22 (41%) 0.3
Hospital length of stay (days) 33(8) 37(11) 0.8
Data is presented in mean (SD), number and percentage.
* Signiﬁcance is p< 0.05, whereas.
** Highly signiﬁcance is p< 0.001.
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Survival Functions
Figure 4 Kaplan–meier survival analysis, Group R showed
shorter time to ABPSPD (acceptable blood pressure and systemic
perfusion days) than Group C.
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synthase (i NOS) has been studied and demonstrated that cyto-
kines had a stimulatory effect on i NOS expression causing
excessive vasodilatation with a suppression effect on e NOS
activity [13].
In vitro studies proved simvastatin and lovastatin increased
the half-life of e NOS under normal or low cholesterol level
[14,15]. Also, in vivo experimental studies showed hydrophilic
rosuvastatin upregulated e NOS expression independent ofTable 3 Safety parameters; number and percentage for serum crea
Safety parameters Group R (n 54)
Serum CPK (number) 5(9%)
Serum transaminases (number) 11(20%)
Serum creatine phosphokinase (CPK) elevation was deﬁned as CPK abo
AST) elevation was deﬁned as elevation in serum transaminases above
indicates signiﬁcant difference between groups.cholesterol level with a protective effect that is equal or supe-
rior to simvastatin and atorvastatin [16].
Several studies investigated the vasopressor effect of statins.
Johannes et al. [17] demonstrated the vaso-protective proper-
ties of simvastatin 8 mg in endotoxemia associated with de-
creased vascular reactivity. Giusti-Paiva et al. determined
pretreatment with simvastatin increased endothelial response
to phenylephrine [18]. McGown et al. [19] reported improved
nitric oxide synthase mediated vessel relaxation by pravastatin
with microvascular anti-inﬂammatory effect which was protec-
tive against sepsis induced hypotension in rats. The protective
effects of statins were evaluated by several studies showing
conﬂicting results, Almog et al. reported the protective effect
of prior statin therapy against severe sepsis [20]. In contrast
Doson Chua et al. [21] found no difference between statin
and non-statin users in septic shock patients (mean duration
of vasopressor support 233 ± 94 h vs. 120 ± 20 h), and this
may be due to the retrospective nature of their study as statin
users had higher incidence of comorbidities. Also Kruger et al.
the use of atorvastatin was not effective on either suppression
of inﬂammatory mediator, improvement in organ dysfunction,
SOFA score or mortality, this may be due to the difference in
study design as well as some patients included in the study
were on statins prior to the study and continued on were this
group was found to show improved survival [22].
In the current study rosuvastatin group showed signiﬁ-
cantly lower lactate and lower dose and duration of norepi-
nephrine than Group C which might be due to better tissue
perfusion as lactate is strongly associated with hypoperfusion
state and MABP h 65 mmHg [23]. Moreover, there was a sig-
niﬁcant decrease in the incidence and duration of invasivetine phosphokinase and serum transaminases.
Group C (n 54) Signiﬁcance
3(6%) 0.1
7(13%) 0.2
ve ﬁve times the upper normal level. Transaminases level (ALT and
three times the upper normal level for the study period. \P< 0.05
316 H.A. El Gendy, N.M. Elsharnoubymechanical ventilation in Group R. In accordance with our
study Fuller et al. [24] reported fewer mechanical ventilation
days in patients with prior statin use than non-statin users
(7.92 vs. 8.49 days, P= 0.0026).
Interventions that shorten ventilation days might eliminate
the risk associated with prolonged intubation and ventilation;
but, our study fails to show signiﬁcant differences in ICU
length of stay, ICU mortality, hospital mortality and hospital
length of stay between the groups. This may be due to complex
pathophysiology of sepsis and the prolonged ICU course mak-
ing the interpretation of the results difﬁcult. These results were
supported by Doson Chua et al. [21] who also failed to demon-
strate difference in ICU and hospital mortality. Whereas
Fernandez et al. [25] showed higher hospital mortality in
mechanically ventilated patients receiving statin therapy. The
lack of statin beneﬁt in their study might be related to the dif-
ferences in patient’s comorbidities, severity of illness, or type
and dose of statin. In contrast other studies associated statin
use with decreased mortality in hospitalized infected or septic
patients. [26,27].
Evaluation of safety of rosuvastatin was assessed using
elevation of serum CPK and transaminases during the study
period, and the number of patients with elevation in transam-
inases and CPK level was not signiﬁcantly different between
groups. In accordance with our results Terblanch et al. [28]
found that the statin groups were not associated with liver cell
failure and ALT was not markedly increased. Also Harris et al.
[29] reported muscle pain without elevation of serum CPK in
about 10% of cases on long standing statin therapy.
The current study has potential limitations though placebo-
controlled study in septic patients, lacked comparison with
other statins, and measurement of rosuvastatin level and fur-
ther study is warranted comparing other statins with different
doses to evaluate the safe vasopressor effect of statins in septic
patients as well as measurement of statin level.
We conclude that rosuvastatin 20 mg/day in septic patients
increased number of days with acceptable blood pressure and
systemic perfusion (ABPSPD), decreased time to initial
ABPSPD, norepinephrine dose and duration, with no signiﬁ-
cant elevation in transaminases or CPK.
Conﬂict of interest
None.
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